Amgen Inc.

Other

The Brigham and Women's Hospital, Inc.

Elan Pharmaceuticals, Inc.

Martin Citron

Dale Bernard Schenk

Peter A Seubert

Peter Andrew Seubert

Brian Drake Bennett

Dennis J Selkoe

Robert James Vassar

Anja Leona Biere

This invention provides methods of screening compounds for their ability to alter the production of A&#x3b2;(x&#x2267;41) alone or in combination with A&#x3b2;(x&#x2266;40). The methods involve administering compounds to cells, specifically measuring the amounts of A&#x3b2;(x&#x2266;40) and A&#x3b2;(x&#x2267;41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.

Methods for determining whether a compound alters the amount of at least one &#x3b1;&#x3b2; (X-41) peptide and the amount of either total &#x3b1;&#x3b2; or at least one &#x3b1;&#x3b2; (X-40) peptide produced by a non-human mammal

Disclosed are novel genes encoding beta secretase polypeptides. Also disclosed are methods of making and using the polypeptides.

Beta secretase genes

Beta secretase polypeptides

This invention provides methods of screening compounds for their ability to alter the production of A&bgr;(x&gE;41) alone or in combination with A&bgr;(x&lE;40). The methods involve administering compounds to cells, specifically measuring the amounts of A&bgr;(x&lE;40) and A&bgr;(x&gE;41) produced by the cells, and comparing these amounts to that produced by the cells without administration of the compounds.

Screening compounds for the ability to alter the production of amyloid-&bgr; peptide

Parkinson's disease (PD) is a neurodegenerative disorder which is pathologically characterized by the presence of intracytoplasmic Lewy bodies, the major component of which are filaments consisting of &agr;-synuclein. The present invention provides &agr;-synuclein mutations which accelerate &agr;-synuclein aggregation and can thus be utilized for transgenic animal production and generation of the first progressive PD model. Also provided is an in vitro aggregation assay which can be utilized to identify &agr;-synuclein nucleation inhibitors for the treatment of PD.

&agr;-synuclein super-mutants accelerate &agr;-synuclein aggregation

Growing community of inventors

Thousand Oaks, CA, United States of America

Martin Citron